The GETUG 15 trial tested whether adding docetaxel chemotherapy to androgen deprivation therapy (ADT) would prolong overall survival in 385 men with hormone-sensitive metastatic prostate cancer. The trial found that adding docetaxel to ADT significantly prolonged both progression-free survival and clinical progression-free survival compared to ADT alone, with median progression-free survival of 23 months versus 13 months and median clinical progression-free survival of 23 months versus 15 months. However, the trial found no significant difference in overall survival between the two groups, with median overall survival of 59 months for those receiving docetaxel plus ADT versus 54 months for ADT alone.

1. GETUG – AFU 15
Dr. Daniel Agüero Velásquez
Residente Oncología Médica
2016

2. The Hypothesis
• Docetaxel added at the time of starting ADT in
hormone-sensitive metastatic prostate cancer
(mHSPC) will prolong overall survival (OS)

3. Metastatic HSPC:
GETUG 15 Trial Design
n = 385 pts
2 ADT:
- LHRH agonist
- or maximum androgen blockade
- or orchiectomy
3 75 mg/m2 q3 up to 9 cycles
Gravis G, et al. Lancet Oncol. 2013;14(2):149-158.
1 Glass TR, et al. J Urol.
2003;169(1):164-169.

4. Median PFS:
ADT + D: 23 mo [19.6-28.4]
ADT: 13 mo [11.9-17.7]
HR [95%CI]: 0.72 [0.57-0.91] P = .0052
ADT+ docetaxel
ADT
ADT
ADT+ docetaxel
Gravis G, et al. Lancet Oncol. 2013;14(2):149-158.
Biochemical Progression-Free
Survival:

5. Median cPFS:
ADT + D: 23 mo [20.5-32]
ADT: 15 mo [12.5-20]
HR [95%CI]: 0.75 [0.59-0.94] P = .0147
ADT+ docetaxel
ADT
Clinical Progression-Free
Survival:
ADT
ADT+ docetaxel
Gravis G, et al. Lancet Oncol. 2013;14(2):149-158.

6. Median OS:
ADT + D: 59 mo [51-69]
ADT: 54 mo [42-NR]
HR [95%CI]: 1.01 [0.75-1.36] P = .95
ADT + docetaxel
ADT
ADT
ADT + docetaxel
Median follow-up: 50 months [49 - 54]
Overall Survival
Gravis G, et al. Lancet Oncol. 2013;14(2):149-158.